The SLTM (SAFB-like transcriptional modulator) antibody targets a protein involved in transcriptional regulation and RNA processing. SLTM, a member of the scaffold attachment factor B (SAFB) family, functions as a nuclear scaffold protein that interacts with RNA polymerase II, chromatin modifiers, and other transcriptional regulators. It plays roles in gene expression control, RNA splicing, and DNA damage response. SLTM shares structural and functional similarities with SAFB1. including a conserved SAF-box domain for DNA/RNA binding and a region mediating protein-protein interactions. Studies suggest SLTM participates in hormone receptor signaling, such as estrogen receptor (ER)-mediated transcription, by acting as a co-repressor or co-activator depending on cellular context. Its involvement in RNA metabolism links it to mRNA stability and transport. SLTM antibodies are essential tools for investigating these processes via techniques like immunoprecipitation, Western blotting, and chromatin immunoprecipitation (ChIP). Dysregulation of SLTM has been implicated in cancer progression and neurological disorders, highlighting its biomedical relevance. Research using SLTM antibodies continues to uncover its dual roles in transcription-coupled genomic stability and RNA biogenesis, bridging nuclear architecture with gene expression networks.